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A B S T R A C T
Background: The introduction of targeted therapies for the treatment of BRAF-mutant melanomas have im-
proved survival rates in a significant proportion of patients. Nonetheless, the emergence of resistance to treat-
ment remains inevitable in most patients.
Scope of review: Here, we review known and emerging molecular mechanisms that underlay the development of
resistance to MAPK inhibition in melanoma cells and the potential strategies to overcome these mechanisms.
Major conclusions: Multiple genetic and non-genetic mechanisms contribute to treatment failure, commonly
leading to the reactivation of the MAPK pathway. A variety of resistance mechanisms are enabled by the un-
derlying heterogeneity and plasticity of melanoma cells. Moreover, it has become apparent that resistance to
targeted therapy is underpinned by early functional adaptations involving the rewiring of cell states and me-
tabolic pathways.
General significance: The evidence presented suggest that the use of a combinatorial treatment approach would
delay the emergence of resistance and improve patient outcomes.
1. Background
Nearly half of cutaneous melanomas carry a genetic mutation that
leads to a substitution in position 600 of the serine/threonine kinase
BRAF [1]. BRAF is a key protein in the Mitogen-Activated Protein Ki-
nase (MAPK) pathway, which regulates several important cellular
functions, including proliferation, differentiation, migration and apop-
tosis. The demonstration of the mutant BRAF oncogene-addiction of
melanomas led to the development of mutant specific BRAF inhibitors
(BRAFis), such as vemurafenib (Zelboraf), dabrafenib (Tafinlar), and
encorafenib (Braftovi) [2–4]. FDA approval and broad clinical use of
vemurafenib and dabrafenib was astoundingly achieved within 10 years
of the BRAF oncogene discovery. Further clinical benefits were gained
from combining BRAFis with MEK inhibitors (MEKis) such as cobime-
tinib (Cotellic), trametinib (Mekinist), and binimetinib (Mektovi), sig-
nificantly improving response rates and overall survival [5–7]. Inter-
estingly, some serious adverse effects, including cutaneous squamous-
cell carcinoma, were attenuated by the combination therapy. However,
nearly all patients treated with single-agent BRAFis, or in combination
with MEKis, eventually developed resistance and relapsed on therapy.
2. Scope of review
In this review, we discuss our current understanding of the me-
chanisms that mediate drug resistance in melanomas treated with tar-
geted therapy. Tumour relapse is driven by a subpopulation of drug-
tolerant cells that persist treatment and remain viable, while the rest of
the population gets killed.
Drug resistance is a multifaceted phenomenon and a complex sce-
nario involving genetic, epigenetic and metabolic changes within the
tumour cells as well as in the tumour microenvironment. Here, we
categorised the various mechanisms underlying treatment failure into
those conferring intrinsic, adaptive and acquired resistance (Fig. 1), and
highlight potential strategies to overcome these mechanisms of re-
sistance.
3. Intrinsic resistance
Around 1 in 5 melanoma patients treated with BRAFis show disease
progression on their first assessment during treatment, despite carrying
a BRAFV600E mutation, indicating the presence of intrinsic resistance in
a substantial proportion of cells within these tumours rendering drug
resistance [8]. Pre-existing genetic alterations and endogenously se-
creted factors from stromal or tumour cells have been identified as
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drivers of intrinsic resistance to BRAF inhibition in some BRAFV600
mutant melanoma cell lines and tumours.
3.1. PTEN loss
Phosphatase and tensin homolog (PTEN) is a tumour suppressor gene,
and a major regulator of the phosphatidylinositol-3-kinase (PI3K)
pathway [9]. Endogenous PTEN mutations and deletions are frequently
identified in BRAF-mutant melanomas [10]. In vitro studies demon-
strated that PTEN loss activates MAPK and PI3K/AKT pathways in
BRAF-mutant melanomas, and confer intrinsic resistance by supressing
the BIM-mediated apoptosis [11]. Moreover, melanoma patients with a
PTEN loss of function alterations/mutations treated with BRAFi
monotherapy or BRAFi plus MEKi were found to have shorter median
progression-free survival (PFS) and overall survival [9,12], but inter-
estingly PTEN loss did not affect overall response rates. In fact, only
10% of PTEN-null BRAF mutant melanomas exhibit intrinsic resistance
to BRAFis [9,13]. The above suggests that PTEN loss contribution to
resistance to BRAFis in melanoma may be contextual, but overall can
reduce treatment effectiveness.
3.2. Amplifications of cyclin D1
In BRAF-mutant melanomas, the activation of MAPK/PI3K path-
ways drives uncontrolled cell proliferation via dysregulation of the RB
pathway (p16INK4A: cyclin D-CDK4/6: RB) [14]. Loss of p16 in mela-
noma cells can occur via deletions (50–80%), inactivating mutations
(16%) and epigenetic silencing (20%) of CDKN2A [14]. In addition, the
CCND1 gene, encoding for cyclin D1, is amplified in 11% of melanomas,
including 17% of BRAFV600E melanomas [15]. Overexpression of cyclin
D1 was linked to resistance to BRAFis in an earlier in vitro study [15]. In
line with this observation, a clinical study found CDKN2A deletion and
CCND1 amplification to be associated with shorted PFS in patients
treated with dabrafenib [12].
3.3. RAC1 mutations
RAC1 is a member of the Rho family of small GTPase that regulates
cell proliferation, cytoskeletal reorganization and cell migration [16].
The RAC1P29S is the third most common hot-spot mutation (4%) in
melanoma after BRAFV600 (50%) and NRASQ61 (20%) [16,17]. The
RAC1P29S is an activating mutation leading to perpetual RAC1 phos-
phorylation resulting in increased cell proliferation and migration [16].
Endogenous RAC1P29S in tumours correlated with early resistance and
lack of response to BRAF inhibition [13]. Silencing the RAC1P29S in
BRAFV600E mutant melanomas restored sensitivity to BRAFis, indicating
the RAC1P29S could be a predictive biomarker to RAF resistance in
melanoma patients [13,18].
3.4. HOXD8 mutations
HOXD8 is a homeobox transcription factor that plays a crucial role
in cell division, adhesion, proliferation, apoptosis and differentiation
[19]. Dysregulated HOX expression has been reported in multiple ma-
lignancies [19]. A HOXD8 mutation was observed in the tumour from
one patient in a comprehensive whole-exome sequencing study of 45
patients with early resistance to BRAFis [13]. In addition, an in vitro
RNAi screening implicated HOXD8 suppression in resistance to a broad
RAF inhibitor [20]. However, the significance of HOXD8 mutations for
BRAFis remain unclear, as no other case has been reported to date.
3.5. MEK mutations
MEK1/2 proteins are downstream components of RAF protein that
promote ERK phosphorylation and MAPK signalling [21]. Pre-existing
MEK1 mutations are present in 5% of the melanomas [10,17]. Pre-ex-
istingMEK1P124 mutations have been attributed to shorter PFS in BRAF-
mutant melanomas treated with BRAFis [22]. In vitro studies identified
the MEK1 mutation, MEK1C121S, confer resistance to BRAFis and MEKis
[21].
Fig. 1. Mechanisms conferring intrinsic, adaptive and acquired resistance in BRAF-mutant melanomas. The numbers within the square brackets represent the
references for each mechanism.
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3.6. NF1 loss
Neurofibromin 1 (NF1) was discovered to play an important role in
the inhibition and suppression of RAS, constraining the MAPK pathway
[20]. Genome scale screening using RNAi and CRISPR-Cas9 have im-
plicated NF1 loss in the resistance to BRAFi and NF1 mutations were
observed in BRAF-mutant tumour cells intrinsically resistant to RAF
inhibition [20,23]. Importantly, endogenous NF1 alterations were
found in pre-treatment tumours of patients who were refractory to
vemurafenib treatment demonstrating the clinical significance of NF1-
driven resistance [20].
3.7. Activation of c-Jun/RHOB axis
Ras homolog gene family, member B (RHOB) GTPase expression are
induced by treatment of BRAF-mutant cell lines with BRAFis, via tran-
scription factor c-Jun [24]. Low basal RHOB expression in melanoma
cells lines correlated with BRAFi sensitivity, while depletion of RHOB
restored sensitivity to MAPK inhibition [24]. Analysis of biopsies from
patients treated with vemurafenib, indicated significantly shorter PFS
in patients whose tumour samples displayed a positive RHOB staining
before treatment compared to those with negative RHOB staining. It is
thought that activation of the c-Jun/RHOB axis affects response to
BRAFis through the activation of AKT pathway [24].
3.8. Factors secreted by tumour microenvironment
3.8.1. Hepatocyte growth factor /c-MET
Increased hepatocyte growth factor (HGF)/c-MET signalling med-
iates melanoma cell proliferation, invasion and offer protection from
apoptosis [25]. In vitro studies demonstrated increased cell proliferation
driven by the stromal HGF/c-MET signalling resulting in the
reactivation of the MAPK and PI3K/AKT pathways, thereby rescuing
melanoma cell lines from RAF and MEK inhibition [25,26]. Treatment
with BRAFis plus HGF/c-MET inhibitors restored the sensitivity of these
cells to BRAF inhibition, supporting the role of HGF signalling in mel-
anoma resistance [25]. A recent study indicated that MAPK inhibition
induced rapid increase in MET and GAB1 levels, priming the tumour
cells for HGF-mediated rescue [27]. In contrast with previous studies
implicating stromal cells in HGF secretion [25], tumour derived HGF
was reported to convey resistance to BRAFis [27]. Nevertheless, treat-
ment with a selective MET inhibitor completely attenuated HGF-
mediated rescue, underscoring the role of the HGF/c-MET axis in
mediating cell survival and resistance.
3.8.2. Hypoxia inducible factor
Hypoxia inducible factor 1α (HIF-1α) is a component of the HIF
transcriptional factor which acts as an oxygen sensing machinery and a
key modulator of the transcriptional responses under hypoxic stress and
excess reactive oxygen species [28]. Under hypoxic conditions, mela-
noma cells exhibited decreased sensitivity to vemurafenib, trending
towards resistance [28]. Proliferative melanoma cell lines exposed to
hypoxic conditions transitioned into an invasive phenotype through a
HIF-1α dependent transcriptional mechanism, indicating the role of
HIF-1α in phenotype switching [29,30]. HIF-1α induced transcriptional
programming has a profound effect on the central carbon metabolism,
increasing glycolytic rates and decreasing mitochondrial respiration
[31].
4. Adaptive response and drug tolerance
Despite the initial tumour reduction observed in most melanoma
patients treated with BRAFis, complete tumour regression occurs rarely.
This is due to the emergence of BRAFi induced compensatory
Fig. 2. Loss of negative feedback regulation of ERK. ERK activation controls MAPK pathway activation through negative feedback loops through the upregulation of
SPRY and DUSP. SPRY inhibits SOS phosphorylation, dampening MAKP activation. BOP1 and STAG are both regulators of DUSP, which inhibits ERK phosphorylation
and maintain control of the MAPK pathway. Loss of function mutations in STAG2, and downregulation of BOP1 results in reduced control of phosphorylated ERK,
allowing cell survival and resistance to BRAFis.
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mechanisms, referred here as adaptive responses, that enhance the pro-
survival and pro-proliferative capacity of a proportion of the original
tumour population. These adaptive responses are temporary responses
that are reversible, and non-transferrable to progenies. Some of the
adaptive mechanisms identified to date include, phenotypic switching
or cell-state transitions, secretion of factors by the tumour micro-
environment, and the more recently trending metabolic reprogram-
ming.
4.1. Loss of negative feedback loops
BRAFi sensitive BRAFV600E mutant cells exhibit low expression of
RAS-GTP before treatment, due to ERK-dependent feedback suppres-
sion of the receptor tyrosine kinases (RTK) signalling [32]. Active ERK
can directly regulate signalling intermediates, such as EGFR and SOS, or
indirectly activate the expression of negative feedback regulators such
as SPROUTY (SPRY) and DUSP proteins [32] (Fig. 2). Inhibition of the
MAPK pathway by BRAFis relieves this feedback, resulting in the re-
activation of multiple pathways and attenuation of the antitumor ef-
fects of the targeted inhibitors [33]. This adaptation occurs within
hours, thus diminishing the effectiveness of the therapy.
From the perspective of BRAFi resistance, it is important to note that
the loss of these kinase-dependent negative feedback loops is unlikely to
solely drive resistance, but they rather facilitate a subpopulation of
tumour cells to survive in an adapted drug-tolerant state.
4.2. Cell-state transitions
The identification of distinctively high and low microphthalmia-
associated transcription factor (MITF) levels within a melanoma tumour
population [34] marked the conceptualization of the MITF-rheostat
model [35]. MITF is a melanocytic-lineage transcriptional factor crucial
for early melanogenesis and differentiation in melanocytes, and iden-
tified a master regulator of several biological processes in melanoma
cells such as invasion, survival, cell cycle regulation and autophagy
[30,36,37].
The MITFhigh population expressed increased levels of MITF down-
stream targets such as MLANA, PMEL, TYRP-1 and TYRP-2 genes, and
are more proliferative and retained sensitivity to BRAFis [34,38,39]. On
the other hand, the MITFlow population expressed genes associated with
invasiveness such as high WNT ligand WNT5A, receptor tyrosine kinase
AXL, TGFβ, TNFα/NF-κβ activation, JUN and TEAD, and conferred
resistance to targeted therapy [35,38,39]. Numerous studies confirmed
the intrinsic resistance conferred by the AXLhigh and MITFlow phenotype
in response to MAPK inhibition in melanoma cells [38–41]. Activation
of markers of invasiveness in the sensitive population reduced the MITF
expression, with cells transitioning into a resistant phenotype.
In notable contrast with the above observations, upregulation of
MITF has been identified as a driver of drug tolerance state and sup-
pression of MITF pharmacologically sensitised the cells to MAPK in-
hibitors (MAPKi) [42]. High expression of MITF and its target genes
(MLANA, PMEL, TYRP-1 and TYRP-2) with BRAFi treatment in BRAF-
mutant melanomas was linked to resistance [43]. Upregulation in MITF
expression as an early driver of non-mutational drug tolerant state in
melanoma cells and linked to intrinsic resistance [13,39,42,44–48], and
PAX3, an upstream regulator of MITF, was identified as a regulator of
MITF expression [42]. Thus, both MITFhigh and MITFlow phenotypes
have been linked to innate resistance in melanoma cells (Fig. 3).
Multiple studies have reported in a phenotypic switch between the
“proliferative” and the “invasive” state in melanoma cells upon BRAFi
treatment and associated with resistance [34,35,49–51]. Interestingly,
such a phenotypic switch was activated by factors secreted by the tu-
mour microenvironment and stress factors contributing to tumour
plasticity [40,52]. Bulk sequencing and, more recently, single-cell RNA
sequencing of melanoma tumours have confirmed the presence of these
different states in individual cell within tumours [51,53]. This
underlying tumour heterogeneity allows for rapid adaptation and sur-
vival of tumour cells early during treatment leading the emergence of
resistance.
4.3. Metabolic reprogramming
Metabolic reprogramming is a hallmark of cancer, driven by onco-
genic signalling pathways or poorly vascularized tumour micro-
environment to meet the increasing cellular biomass needs [54]. BRAF-
mutant melanoma cells exhibit high glycolytic activity and decreased
mitochondrial respiration, to meet the increasing biomass and ATP
needs of high proliferative cells [55]. The Warburg phenotype in mel-
anomas is partially driven by the MAPK or PI3K pathway by increasing
the production of HIF-1α and MYC and promoting glycolysis or in-
hibiting MITF, a key regulator and promoter of oxidative phosphor-
ylation (OXPHOS) in tumour cells [31]. Treatment with BRAFis and
MEKis triggers metabolic programming in the BRAF-mutant cells to
reduce glycolysis and increase mitochondrial respiration by activating
MITF-PGC1α-OXPHOS pathway. Evidence of increased peroxisome
proliferator-activated receptor γ coactivator 1α (PGC1α) levels, a
marker of elevated OXPHOS, was exhibited by melanoma patients
treated with single-agent BRAFi and in combination with MEKi [44,45].
KDM5B (JARID1B) expression has been indicated as a marker of these
slow-cycling BRAFi resistant cells with increased oxidative phosphor-
ylation [56]. Endogenous JARID1B and PGC1α overexpressing cells in
patient tumours demark a subset of cells with increased mitochondrial
capacity and resistance to oxidative stress that survive BRAFi [57,58].
In addition to the alteration in the glycolysis pathway, MAPK in-
hibition alters the fatty acid oxidation (FAO) in BRAF-mutant mela-
noma cells, which supply the structural material for cell and organelle
membranes [59]. Short-term treatment with MAPK inhibition led to
upregulation in fatty acid transporter CD36 in BRAF-mutant melanoma
cells and PPARα-mediated and carnitine palmitoyl transferase 1A
(CPT1A)-dependent FAO [59]. In parallel, fatty acid synthase, a key
enzyme in endogenous fatty acid synthesis, is indirectly activated by
the MAPK and PI3K pathways [60]. Thus, the continuous signal for cell
proliferation is supported by multiple metabolic pathways.
4.4. ER stress and autophagy
The nuclear translocation and reactivation of ERK drive a non-
canonical ER stress response via ATF4 phosphorylation, to induce cy-
toprotective autophagy. Dephosphorylation of ERK activates the
translocation of MAPK components from the cytoplasm to the ER by
GRP78 (molecular chaperone), KSR2 (scaffolding protein), early en-
dosomes and SEC6 (ER translocase) [61,62]. This translocation is re-
quired for the re-phosphorylation of ERK in the cytoplasm, which is
carried out by the cytoplasmic lipid kinase domain of pERK [62].
Autophagy can be promoted by the activation of the MAPK pathway
[63,64] or by the LBK1-AMPK pathway to rescue the cells from glucose
starvation [65]. BRAF inhibition also induces autophagy by the acti-
vation of the transcriptional factor, TFEB [66]. The “BRAF-TFEB-au-
tophagy-lysosome” axis constitutes an intrinsic regulatory pathway in
BRAF-mutant melanoma, coupling BRAF signalling with TGF-β signal-
ling to drive tumour progression and chemoresistance [66].
5. Acquired resistance
Around 50% of patients treated with BRAFis alone or in combina-
tion with MEKis experience an initial significant shrinking of the tu-
mour followed by tumour outgrowth, due to the emergence of acquire
resistance. This resistance often spawns from the acquisition of a mu-
tation that either reactivates the MAPK pathway or circumventing the
MAPK pathway altogether through the utilisation of alternative path-
ways to support cellular growth.
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5.1. MAPK reactivation-based survival
5.1.1. Receptor Tyrosine Kinases
Receptor tyrosine kinases (RTKs) act as upstream activators of
MAPK signalling. Nazarian et al. first demonstrated that increased ex-
pression of PDGFRβ conferred resistance to BRAFis [67], which was
further demonstrated by others using different cell lines [68,69]. In
contrast, another study showed increased expression of EGFR, KIT and
MET with decreased expression of PDGFRβ in resistant M249 cells [70].
Supra-physiologic levels of c-MET transcripts have been found BRAFi
resistant melanomas [71]. A study by Shaffer et al. suggested that
multiple RTKs, such as AXL, EGFR, PDGFRβ and JUN are expressed in
small subpopulation of melanoma cells prior treatment by non-heri-
table, transient expression [41]. BRAFi treatment selects for an in-
creased proportion cells expressing these RTKs, which mediate re-
sistance through the activation of the MAPK pathway or alternative
PI3K/AKT pathway.
5.1.2. NRAS and MEK mutations
NRAS serves as an activating mutation within melanoma encom-
passing around 28% of melanomas, with Q61R being the most common
[10]. NRAS mutants preside within both combinational and mono-
therapy cohorts [67,72]. NRAS mutations as a resistance mechanism
have an occurrence of 5–18% [73–75]. Resistant cells with secondary
NRASQ61K mutation require CRAF expression and SHOC2 scaffold pro-
tein to re-activate MAPK [76]. BRAF inhibition specifically, not drug
binding, drives wild-type BRAF binding to CRAF and activation of MEK
[77]. Despite the theoretical and preclinical support for CRAF over-
expression to mediate BRAFi resistance it has yet to be reported within
clinical samples [78].
MEK1mutations are rare in melanoma and are often associated with
either BRAF or NRAS mutations [10]. MEK1 mutations within either
exon 3 or 6 were found to confer resistance to BRAF inhibition [79].
Further studies also supported that MEK1 mutations in BRAFV600E
melanomas are linked to both intrinsic and acquired resistance to
BRAFis [22,80]. Various meta-analysis studies have described an
Fig. 3. Distinctive phenotypic states and metabolic signatures in BRAFi treated melanoma cells. Highly proliferative BRAFi sensitive cells exhibit high glycolysis rate
and high MITF. BRAFi resistant cells are characterised by OXPHOS activation but can exhibit two distinct cellular states with either high or low MITF. In the MITFhigh
state high OXPHOS is driven PGC1α activation, while the MITFlow state is characterised by high AXL and NFKβ, with a high OXPHOS signature driven by JARID1B
expression.
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overall incidence of 7–8% for MEK1/2 mutations in BRAFi mono-
therapy and BRAFi plus MEKi -resistant melanomas [72,73]. In con-
trast, Shi et al. showed that pre-existing exon 3 mutations, MEKP124S
and MEK111S, do to not confer resistance to vemurafenib [81]. It has
been postulated MEK1 exon 3 mutations are not constitutively acti-
vating but render MEK1 more readily activated. Further studies are
required to disentangle the role of MEK mutations in pathogenesis and
treatment resistance of melanoma.
5.1.3. BRAF amplification
The overproduction of BRAFV600E due to the genetic amplification
of the mutant gene has been established as a common mechanism of
resistance to both BRAFi or BRAFi plus MEKi [72,82], confirmed by
various large studies of clinical specimens [72–75]. BRAFV600E ampli-
fication drives resistance through the excess generation of activated
MEK, which in turn activates downstream constitutes of the MAPK
pathway. BRAF amplification and alternative splicing were observed
most frequently followed by NRAS mutations and MEK1/2 mutations
[73].
5.1.4. BRAF splicing variants
Resistance to the BRAFis can also be conferred through the pro-
duction of aberrantly spliced BRAFV600E isoforms that lack the RAS
binding domain (RBD) encoded by exons 3–5 [83]. These splicing
variants lacking the RBD, can dimerize in the presence of low levels of
RAS and confer drug resistance [83]. Four BRAF splicing variants have
been described, referred as p61, p55, p48 and p41 based on their pre-
dicted molecular weight. Alternative BRAF spliced isoforms have been
identified in patients progressing on BRAFi alone and in combination
with MEKis and as in preclinical models [83–86]. In fact, expression of
aberrantly spliced BRAF V600E isoforms mediates resistance in 13–30%
of melanoma patients [73–75]. Although BRAF splicing variants are
capable of conferring resistance to BRAFi, cell line studies have shown
that melanoma cells carrying splicing variant remained susceptible to
MEK inhibition [72]. Moreover, enhanced association between BRAF
splicing variants and their substrate, MEK, that is required for re-
sistance to BRAFis [87].
5.1.5. COT alterations
The Ser/Thr MAP kinase MAP3K8 (or COT) has the potential to
directly phosphorylate MEK to trigger downstream cascades.
Johannessen et al. reported that COT expression was associated with
acquired resistance to BRAFi in melanoma cell lines and tissue obtained
from relapsing patients following treatment with MEKis or RAF in-
hibitors [88]. Over activation of MEK within the cell line A375 was
established to occur through COT signalling, also generating resistance
to the MEKis, selumetinib and CI-1040 [88].
5.1.6. STAG 2 and 3 alterations
Loss-of-function mutations in STAG2 and decreased expression of
STAG2 and STAG3 proteins in several tumour samples from patients
with acquired resistance to BRAFi and in BRAFi-resistant melanoma cell
lines [89]. Furthermore, STAG3 mutations were found 3/14 pre-treat-
ment samples of patients who developed resistance vemurafenib within
12 weeks of treatment and the post-relapse sample of another 6 cases
[89], suggesting STAG2 mutations to mediate intrinsic as well as ac-
quired BRAFi resistance (Fig. 2). STAG2 knockdown let to decreased
dual-specificity phosphatase 6 (DUSP6). DUSP6 acts as a negative
regulator of ERK activation [90]. Thus, STAG2/3 alterations result in
ERK activation, by limiting dephosphorylation.
5.1.7. BOP1 downregulation
The ribosome biogenesis protein Block of Proliferation 1 (BOP1)
acts as a regulator of DUSP4 and DUSP6 [90,91]. Unlike STAG
knockdown, which saw a reduction in DUSP6 but not DUSP4, loss of
BOP1 generated a reduction in both, leading to an increase in MAPK
signalling [89,91] (Fig. 2). A small scale investigation into patient
samples both pre and post BRAFi alone or in combination with MEKi
revealed a reduced protein expression of BOP1 within 7 of the 11 cases
that relapsed [91]. The results of this study, though initial highlight
another escape mechanism that can be utilised by melanomas.
5.2. MAPK independent based survival
5.2.1. PI3K-AKT pathway
Another established pathway is the PI3K/AKT pathway [92]. The
induction of the PI3K-AKT by insulin could protect BRAFV600E cells
from vemurafenib [93]. Cross-talk between the PI3K and MAPK path-
ways has been established, with BRAFi resistant cell lines utilising AKT
to trigger ERK within MAPK for cell survival, circumventing both
BRAFis and MEKis [94]. AKT1 mutant based resistance to BRAFis has
been identified previously in progressive patient samples to mono-
therapy [74]. Recent work demonstrated that PI3K activity is capable of
promoting survival but not proliferation of cell lines when challenged
with BRAFis plus MEKis [95].
5.2.2. WNT5A/β-catenin pathway
Continuous BRAFi in BRAF-mutant cell lines results in elevated
WNT5A transcripts. Furthermore, 7 out of 11 tumours from patients
who progressed in BRAFis presented increased WNT5A expression
compared to pre-treatment samples [96]. In vitro studies demonstrated
that a loss of WNT5A reduced the viability of the cells in the presence of
BRAFis [96]. WNT5A overcomes BRAF inhibition through the increased
phosphorylation of AKT and activation of RYK and FZD7 receptors
supporting non-canonical WNT signalling [96].
6. Potential strategies to overcome resistance
As discussed above, intrinsic and acquired resistance primarily in-
volve the reactivation of the MAPK pathway. Concomitant inhibition of
the BRAF and MEK nodes to overcome the MAPK signalling from hy-
peractivation of MEK has shown increase PFS, but still emerge similar
resistance mechanisms [72]. Reactivation of ERK is central to most
acquired resistance mechanisms. Thus, next generation ERK inhibitors
have been suggested as a suitable target for effective MAPK inhibition,
with molecules such as LY3214996 (NCT02857270) and BVD-523
(NCT02465060) progressing into clinical trial [97]. However, the suc-
cess of this approach remains uncertain considering the role of feedback
loops such as DUSP/SPRY which could lead to reactivation of the MAPK
pathway [32].
To address the upregulation of RTK as mechanism of resistance,
combination of BRAF/MEK blockade with RTK inhibitors (e.g.,
LY3022855, lapatinib and foretinib) are currently in trials to prevent
the MAPK reactivation (NCT03101254, NCT03455764) [98]. Increased
RTK signalling was reported to activate SRC/FAK/STAT3 signalling
leading to invasive phenotype [99]. Thus, combination of BRAF/MEK
blockade with SRC, FAK or STAT3 inhibitors (SAB298, saracatinib)
have been suggested to target the BRAFi-resistant melanoma population
with high dedifferentiated state or invasive phenotype [99].
Combination of BRAFi/MEKi with PI3K inhibitors have been trialled
to block the activation of parallel signalling by the AKT/PI3K pathway,
but found associated with increased toxicities or unmet therapeutic
goals due to rapid clearance [100]. Alternatively, combination of mTOR
inhibitors with BRAFi was thought to be effective in tumours with
PI3K/AKT pathway activation, by inducing apoptosis. Preclinical evi-
dence also demonstrated that the combination of mTOR inhibitors with
MAPKi to desensitise the high MITF expressing cells with high OXPHOS
and mitochondrial activity [45]. Initial phase I trials showed positive
outcome with limited toxicity (NCT01596140) [101], but treatment
efficiency evaluation in larger cohort of molecularly matched patients is
still needed. Another approach trialled in overcoming intrinsic and
acquired resistance is the combination of MAPK inhibition and
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apoptosis induction by targeting molecules such as BCL-2 family pro-
tein (NCT01989585), CDK4/6 (NCT02645149) [102], histone deace-
tylase (NCT02836548) and heat shock protein 90 (NCT02097225)
[103].
Acknowledging the understanding that cell plasticity enables the
survival of a dormant population of MAPK-inhibited melanoma cells,
multiple approaches have been tested to overcome adaptive resistance.
For example, the combination of BRAFi with hydroxychloroquine is
able to re-sensitise resistant cells by inhibiting cytoprotective autop-
hagy induced by the ER stress response (NCT03754179) [61]. Other
strategies have involved the inhibition of PAX3 mediated MITF upre-
gulation using the HIV protease inhibitor nelfinavir [42], or by tar-
geting AXL with the antibody conjugate AXL-107-MMAE [104]. On the
other hand, nicotinamide phosphoribosyl transferase inhibitors and the
combination of FAO and glycolysis inhibitors, may avoid the early
metabolic reprogramming induced by MAPKi that underscores adaptive
resistance [59,105].
Despite the multiple alternatives being tested, the benefits of these
approaches might not be apparent in a clinical setting when patients
harbour multiple active resistance mechanisms [106]. Clinical and
preclinical evidence has demonstrated diverse resistance mechanisms
within the same tumour, underscoring the contribution of genomic
heterogeneity to BRAFi treatment failure. Hence, early treatment in the
adjuvant setting may be the best strategy to avoid the emergence of
resistance. In line with this, the introduction of combination MAPKi
therapy into stage III melanoma has had a significant impact in the
prevention of relapse post intervention [107].
7. Major conclusions
Overall, acquired resistance to BRAF inhibition depends on onco-
genic signalling through reactivation of MAPK or activation of alter-
native pathway such as the PI3K/AKT pathway. Resistance can be ac-
quired by upregulation of receptor tyrosine kinases signalling, by
directly affecting genes in these pathways, or by enhancing downstream
signalling. However, the mechanisms underlying acquired drug re-
sistance are hugely diverse, with evidence of high inter- and intra-tu-
mour heterogeneity [75]. These resistance mechanisms are distinct to
those observed following targeted therapy treatment in other cancer
types. For example, no secondary “gatekeeper” threonine mutations in
BRAF have been observed, which is a common resistance mechanism to
other kinase inhibitors [108,109].
As reviewed above, multiple studies have identified numerous me-
chanisms of resistance in patients failing single-agent BRAFis or in
combination with MEKis. Interestingly, the vast majority lead to the
reactivation of the MAPK pathway underscoring its importance for
melanoma cell maintenance [110]. In addition, to those events ob-
served only in treated tumours (acquired resistance), several resistance
effectors already exist in pre-treatment samples (intrinsic resistance), in
some cases constituting a tumour cell subpopulation. However, cumu-
lative they still failed to explain all the observed clinical relapse cases.
Thus, further studies are needed to elucidate the complete landscape of
resistance mechanisms.
The picture is less clear for cellular processes conferring adaptive
resistance. Prior to relapse, targeted therapy induces cellular adapta-
tions to survive treatment, and within these cells acquire mechanism of
resistance develops. Now it is better understood the role of tumour
plasticity and metabolic reprogramming in these adaptation processes
[51,111–113]. This has led to new treatment paradigms suggesting the
combination of oncogenic inhibitors with metabolic targets. This may
provide effective control of tumour growth, by avoiding the survival of
cell subpopulations from which acquired resistance may emerge.
Finally, the emergence of effective immunotherapies provides al-
ternative treatments with the potential to deliver long term control of
melanoma growth [114]. The identification of increased tumour im-
mune infiltrate in BRAFi treated melanomas, combination with
immunotherapies were thought to enhance tumour control
(NCT02902042, NCT02858921). However, these combinations have
significant associated toxicities [115]. Sequential administration of
targeted and immunotherapy also has its limitations, with translational
studies suggesting that an immuno-resistant phenotype emerges on
progression after BRAF inhibition [116]. Moreover, innate and adaptive
BRAFi resistance mechanisms overlap with that found in tumours
failing immunotherapy such as MITF/AXL programming, WNT pathway
activation and PTEN loss [117]. In this context, the rationale for
treatment selection may need to be based on the phenotypic and mo-
lecular characteristics of the pre-treatment tumours, which requires a
clear and comprehensive understanding of the mechanism mediating
resistance.
8. General significance
Although treatment with BRAFis provides rapid response in most
melanoma patients, at present the emergence of resistance remains
unavoidable. Numerous studies have addressed the mechanisms un-
derlying the rapid emergence of resistance, but only half of these cases
can be explained by the known mediators. Preclinical studies support
the mechanisms observed in patients, indicating that the development
of resistance is more complex than a single mutation. Further studies
are required to better understand BRAFi resistance and to aid the de-
veloping strategies that can retain long-term durable responses of
combination therapy.
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